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COMMENT
THE TEST OF PRIMARY CLONING: A NEW
APPROACH TO THE WRITTEN DESCRIPTION
REQUIREMENT IN BIOTECHNOLOGICAL PATENTSt
Jennifer L. Davisl
I. INTRODUCTION
To secure a patent for an invention, one of the most fundamental
requirements is an adequate description of the invention in words.'
Not only does the description help a patent examiner determine
whether the invention meets the requirements for patentability,2 but
more importantly, it tells the world what has been invented as of the
filing date of the patent application.3  It serves one of the main
objectives of the patent system: fostering the exchange and sharing of
ideas such that others may build and improve upon the creations of
others.4 The written description requirement is codified in the patent
t This comment won First Place in the 2003 SANTA CLARA COMPUTER & HIGH TECH.
L.J. Comment Contest.
T The author is a third year law student at Santa Clara University School of Law and is
a Senior Production Editor for the SANTA CLARA COMPUTER & HIGH TECH. L.J. Following
graduation, Ms. Davis will join the intellectual property law firm of Finnegan, Henderson,
Farabow, Garrett & Dunner in Palo Alto, California. The author received her Ph.D. degree in
Biology from Johns Hopkins University and B.S. degree in Genetics from the University of
California, Davis. Prior to law school, Ms. Davis was employed in the biotechnology industry,
initially in molecular biology research and later in business development. The author thanks
Professor June Carbone for critical reading of the manuscript and helpful suggestions.
1. 35 U.S.C. § 112 para.l (2000); Enzo Biochem, Inc. v. Gen-Probe, Inc., 285 F.3d
1013, 1021 (Fed. Cir. 2002) (hereinafter Enzo I), vacated by 296 F.3d 1316 (Fed. Cir. 2002)
(hereinafter Enzo 11).
2. Enzo I1, 285 F.3d at 1022 (stating "[a]n adequate description is necessary for proper
examination of an application").
3. Guidelines for Examination of Patent Applications Under the 35 U.S.C. § 112, para.
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statute5 and has been interpreted by courts in various ways throughout
history within the context of specific technological fields.
In the biotechnology arena, the Court of Appeals for the Federal
Circuit (CAFC) has interpreted the written description requirement in
the context of claims to nucleic acid sequences on several occasions.
Each decision seems to bring forth a new pronouncement regarding
the sufficiency of a written description for such claims. This has lead
to confusion in the legal community, even among members of the
court as evidenced by a reversal, three months after the first decision,
by the same panel of judges.6 Thus, it is currently not clear whether
an inventor must demonstrate possession of the invention,7 list the
sequence of the claimed nucleic acid,8 or support the claim by
describing functional properties of the sequence correlated with other
known attributes.9
The conflicting decisions and lack of clear standards has led to
debate in the legal community regarding how the written description
requirement should be applied to nucleic acid sequence claims.'° This
comment will explore the controversial CAFC decisions as well as the
two sides of the debate. Then, noting that both sides of the debate
have merit, this paper concludes with a proposal reconciling the sides
by providing a novel test for nucleic acid sequence claims, dubbed the
primary cloning test. The primary cloning test addresses the dual
nature of nucleic acids as molecules amenable to scientific discovery
and isolation from their natural sources, and, secondarily, as
molecules of laboratory experimentation. This test is then applied to
the Enzo patent" currently pending before the district court on
remand from the CAFC. 12 The primary cloning test creates a new,
5. 35 U.S.C. § 112, para. 1.
6. Enzol, 285 F.3d at 1013, vacatedbyEnzo 11, 296 F.3d at 1316.
7. Fiers v. Revel, 984 F.2d 1164, 1167 (Fed. Cir. 1993); but see Enzo 1!, 296 F.3d at
1330.
8. Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1566-67 (Fed. Cir.
1997).
9. Enzo ll, 296 F.3d at 1324-25; but see Lilly, 119 F.3d at 1568.
10. See, e.g., Janice M. Mueller, The Evolving Application of the Written Description
Requirement to Biotechnological Inventions, 13 BERKELEY TECH. L. J. 615 (1998); Arti K. Rai,
Intellectual Property Rights in Biotechnology: Addressing New Technology, 34 WAKE FOREST
L. REV. 827 (1999) (both contending that a narrow application of the written description
requirement is deleterious); but see, e.g., Margaret Sampson, The Evolution of the Enablement
and Written Description Requirements Under 35 U.S.C. 112 in the Area of Biotechnology, 15
BERKELEY TECH. L.J. 1233 (2000) (contending that a narrow application of the written
description requirement is beneficial).
11. U.S. Patent No. 4,900,659 (issued Feb. 13, 1990) (hereinafter '659 patent).
12. Enzoll, 296F.3dat 1316.
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bright-line criterion to guide consideration of the adequacy of the
written description supporting nucleic acid sequence claims.
A. Some Basics of the Science Underlying the Biotechnology
Industry
Before discussing the written description requirement as it
relates to nucleic acid sequence claims, a basic review of the
underlying science and its application to biotechnology is provided.
The starting point for the modem biotechnology industry was the
discovery that deoxyribonucleic acid (DNA) can be recombined in a
way allowing for the inexpensive and efficient mass production of
proteins encoded by the recombined DNA.1 3  DNA is the
informational chemical found in each living cell that determines the
physical characteristics and properties of that cell and provides the
basis for transmission of heritable traits to progeny.1 4  The
informational aspect of DNA is inherent in its chemical structure. 15
Four different types of chemical building blocks known as
nucleotides (adenine [A], guanine [G], cytosine [C] and thymine [T])
are linked together via a phosphate backbone. 16  The now-famous
DNA double helix structure consists of two complementary DNA
strands paired together through chemical bonds between the
nucleotides. 17  The nucleotide A always pairs with T and the
nucleotide G always pairs with C.18  The structure allows for the
faithful copying of genetic information and transmission of copied
information to progeny. 19 DNA is divided into functional units called
genes.20 Genes encode proteins that do the work of the cell.21 Only a
small portion of DNA actually encodes proteins, the rest of the DNA
molecule provides structural and other functional signals. 22 The
13. See, e.g., STEPHEN S. HALL, INVISIBLE FRONTIERS, THE RACE TO SYNTHESIZE A
HUMAN GENE (1987), (chronicling the early events in university labs, start-up biotechnology
companies and the pharmaceutical company, Eli Lilly & Co., to generate recombinant human
insulin); MOLECULAR CELL BIOLOGY 244-46 (Harvey Lodish et al. eds., 2000).
14. LODISH, supra note 13, at 3-5.
15. Id. at 100-01.
16. Id. at 101-03.
17. Id. at 103.
18. Id.
19. Id. at5.
20. LODISH, supra note 13, at 3-5.
21. Id.
22. See generally International Human Genome Sequencing Consortium, Initial
Sequencing and Analysis of the Human Genome, 409 NATURE 860 (2001); J. Craig Venter et al.,
The Sequence of the Human Genome, 291 SCIENCE 1304, 1334-45 (2001).
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synthesis of proteins requires the generation of an intermediate
molecule, messenger ribonucleic acid (mRNA). Messenger RNA is a
single stranded copy of the protein-coding part of the DNA from
which it is derived and the nucleotide sequence of the mRNA
determines the protein that will be made.23
A key discovery enabling the birth of the biotechnology industry
was that stable DNA copies of mRNA, called complementary DNA
(cDNA), can be made using certain proteins derived from viruses.24
When cDNA is recombined (or cloned) in a specialized DNA
molecule known as a vector and inserted into a host cell, the host cell
is transformed into a living factory for production of the protein
encoded by the particular cDNA.a5 This is the essence of the modem
biotechnology field that produces recombinant proteins, such as
insulin and growth hormone, for therapeutic use.26
It would be impossible to create recombinant vectors containing
cloned cDNA without methods to "see" the DNA, isolate it and
manipulate it in the laboratory. Many such methods are based upon
another key discovery pertaining to a chemical property of DNA.27
This property is that the two strands of the double helix can be
separated from each other temporarily and then be brought back
together again.28 DNA separation occurs naturally in the cell 29 and
this property of DNA has been exploited experimentally as described
below.
In the laboratory, any two complementary single-stranded
nucleic acid chains, whether composed of DNA or RNA, can be
induced to pair with one another through the chemical bonding of A's
with T's 30 and C's with G's in a reaction known as hybridization.
31
Thus, an investigator can prepare a labeled (usually using a
radioactive or fluorescent tag) nucleic acid probe and follow it during
23. LODISH, supra note 13, at 5.
24. See, e.g., HALL, supra note 13, at 18-19; LODISH, supra note 13, at 219-21.
25. LODISH, supra note 13, at 227.
26. See, e.g., HALL, supra note 13, at 18-19.
27. See, e.g., MOLECULAR BIOLOGY OF THE CELL 188-96 (Bruce Alberts et al. eds., 2d
ed. 1989).
28. Id. at 188.
29. The strands of DNA separate in the cell during the process of DNA replication in
which a complete copy of all nuclear DNA (in the form of chromosomes) is made for passage to
a new daughter cell. Likewise, the strands of DNA separate during the process of RNA
synthesis, including mRNA synthesis. See, e.g., ALBERTS, supra note 27, at 514-527.
30. In the case of RNA, thymine is replaced by uracil, so adenine bonds with uracil. See,
e.g., ALBERTS, supra note 27, at 98.
31. See, e.g., ALBERTS, supra note 27, at 188.
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an experiment.32The probe is a single stranded nucleic sequence that
hybridizes to a DNA or RNA strand that is its exact partner for
pairing between the nucleotides, also known as the complementary
strand. As an example, if the target DNA sequence is ACGTGC, then
the probe sequence that will hybridize to the target is TGCACG.
Such hybridization reactions between probe and target nucleic acid
sequences have been exploited to study a number of cellular and
biochemical processes as well as to clone genes and to perform
numerous experimental procedures.33
In addition, it is known that experimental parameters, such as
temperature and salt concentration, can be altered to lessen the
fidelity of pairing between nucleotides.34 If the target DNA sequence
is ACGTGC as in the hypothetical example above, but the probe
sequence contains a one base mismatch and reads TGTACG, it can
still be induced to hybridize to the target by simply modifying the
experimental parameters. This has been exploited to clone genes of
distantly related organisms using the first cloned member of a gene
family as a probe to isolate other members of the family even though
the gene sequences are non-identical.35
Today, recombinant DNA technology and the resulting
biotechnology industry have grown to encompass a wide array of
activities including the creation of new research tools, diagnostic
tests, agricultural products, veterinary products and human
therapeutics. Therefore, a precise definition of biotechnology for the
purpose of discussion is required. Here, biotechnology takes a very
limited definition and means solely the cloning and manipulation of
nucleic acid molecules. 36 This definition is chosen because the cases
discussed at length in this paper pertain to patents with claims to
nucleic acid sequences and because claims to nucleic acid sequences
continue to dominate the scientific and legal interface.
32. Id. at 189.
33. Id. at 188-96.
34. Id. at 188-93.
35. Id. at 191-92.
36. Nucleic acids refer to both DNA and RNA molecules, both of which are linear
strings, or polymers, of nucleotides. A nucleotide consists of a nitrogen containing base linked
to a sugar and one or more phosphate groups. RNA differs from DNA in that the sugar
phosphate backbone contains ribose instead of deoxyribose, it contains the base uracil instead of
thymine, and it is single-stranded instead of double stranded. See, e.g., ALBERTS, supra note 27,
at 98.
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II. DEFINING THE WRITTEN DESCRIPTION CONTROVERSY IN
BIOTECHNOLOGICAL (NUCLEIC ACID SEQUENCE) PATENTS
A. The Written Description Requirement in Biotechnological
Patents
The patent statute states the written description requirement as
follows:
The specification shall contain a written description of the
invention, and of the manner and process of making and using it, in
such fill, clear, concise, and exact terms as to enable any person
skilled in the art to which it pertains, or with which it is most
nearly connected, to make and use the same, and shall set forth the
best mode contemplated by the inventor of carrying out his
invention.
37
The courts have interpreted this language in different ways over
time. Before the advent of biotechnology, the written description
requirement was first ancillary to enablement-it was to enable one
skilled in the art to make and use the invention.38 The written
description also served to put the public in possession of the
invention.39  Later, the written description was employed in the
context of claims added or amended after filing the application. 40 The
inventor was limited to adding or amending claims to the extent they
were supported by the written description of the originally filed
application. 4' Thus, the written description served as notice of what
the inventor possessed at the time of filing and therefore prevented
overreaching, that is, claiming subject matter that the inventor did not
actually invent.4 2
In the context of biotechnology, one of the early cases that
examined the written description requirement was Fiers v. Revel.
43
This case was a three-way priority contest pertaining to DNA
encoding human beta-interferon. Revel's patent application disclosed
methods for isolating DNA and mRNA coding for beta-interferon, but
did not disclose a complete beta-interferon DNA sequence.44  The
37. 35 U.S.C. § 112, para.l.
38. Evans v. Eaton, 20 U.S. (7 Wheat) 161, 196 (1822).
39. Id.
40. In re Ruschig, 379 F.2d 990, 992-93 (CCPA 1967).
41. Id.
42. Id. at 995-96.
43. 984 F.2d 1164 (Fed. Cir. 1993).
44. Id. at 1167.
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court found the written description inadequate to support a claim to
the entire coding sequence 45 using the test of whether the disclosure
conveys to one skilled in the art that the inventor possessed the
invention claimed.46  In addition, the court enunciated written
description guidelines adequate for claiming DNA sequences
explaining that "what is required is a description of the DNA itself.
' 47
A description of the DNA is shown by reciting a "structure, formula,
chemical name, or physical properties, ''48 not merely by disclosing "a
plan, for obtaining the DNA."' 9
The next case to address written description in the context of
biotechnological patents was Regents of the University of California.
v. Eli Lilly & Co., which also involved a priority contest over DNA
sequences.50 The University of California (U.C.) alleged that Lilly
infringed a patent claiming cDNA encoding human insulin.51 The
patent specification described a method for isolating and cloning
human insulin cDNA, along with the amino acid sequence of the
insulin protein, but did not disclose any sequences corresponding to
the human insulin cDNA, the claimed invention. 52  Citing the
language in Fiers that DNA is described by reciting a "structure,
formula, chemical name, or physical properties, 53 the court held that
the claim was invalid for failing to provide an adequate written
description.54 The disclosure was found to be a general method for
obtaining the cDNA, not a description of the cDNA itself.55
Furthermore, U.C. contended that the disclosure was adequate
because additional claims broadly covered vertebrate insulin cDNA
and mammalian insulin cDNA, and the sequence of rat insulin cDNA,
a species within both vertebrate and mammalian genera, was
provided.56 The court rejected this argument finding that a sequence
to one member of a genus, without more, did not describe the entire
45. Id. at 1171.
46. Id. at 1170.
47. Id.
48. Id. at 1171.
49. Fiers, 984 F.2d at 1171.
50. 119 F.3d 1559 (Fed. Cir. 1997).
51. Id. at 1562-63.
52. Id. at 1567.
53. Fiers, 984 F.2d at 1171.
54. Lilly, 119 F.3d at 1566-67.
55. Id. at 1567.
56. Id.
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genus." The entire genus was described only by function, in other
words, the genus was described by what it did and not by what it
was. 58 Thus, the court held these claims invalid as well.
5 9
B. The Enzo I and Enzo H Decisions of 2002 Demonstrate
Judicial Confusion over the Written Description
Requirement in Biotechnological Patents.
The Lilly decision discussed above generated much debate in the
legal community with some commentators arguing that it imposed a
heightened requirement upon biotechnological patents that would
hinder innovation and hurt the industry60 while others argued that
Lilly was correctly decided and would prevent overreaching by
inventors thereby fostering the growth of the industry. 61 These points
are discussed in greater detail below. But perhaps the most
unfortunate aspect of the Lilly decision was that while it clearly
signaled the importance of supporting nucleic acid claims with an
adequate written description, it failed to articulate clear and definite
standards by which to do so. Nowhere is this more evident than in the
2002 Enzo decisions in which the CAFC initially found the written
description supporting claims to DNA sequences inadequate in Enzo
/,62 and then, upon rehearing, reversed the decision in Enzo 11.63
The patent at issue in the Enzo decisions was directed to DNA
sequences that distinguish the bacterial causative agent of gonorrhea,
Neisseria gonorrhoeae, from its closely related cousin, Neisseria
meningitides, based on the ability of the DNA of the invention to
preferentially hybridize to the genome of N. gonorrhoeae.64 Three of
the cloned DNA sequences belonging to the claimed genus were
deposited in the public repository, the American Type Culture
Collection (ATCC). 65 None of the DNA molecules of the invention
57. Id. at 1568.
58. Id.
59. Id. at 1570.
60. See, e.g., Mueller, supra note 10, at 615; Rai, supra note 10, at 827.
61. See, e.g., Sampson, supra note 10, at 1236.
62. Enzo Biochem, Inc. v. Gen-Probe, Inc., 285 F.3d 1013, 1021 (Fed. Cir. 2002)
(hereinafter Enzo 1), vacated by 296 F.3d 1316 (Fed. Cir. 2002) (hereinafter Enzo 11).
63. Enzo11, 296 F.3d at 1316.
64. '659 patent, supra note 11.
65. The deposit of biological materials for patent purposes is governed by regulations set
forth at 37 C.F.R. §§ 1.801-1.809; ATCC is a global, nonprofit bioresource center established in
1925 and located near Washington D.C. It maintains stocks of all types of biological materials
received from scientists around the world. These include recombinant DNA clones for genes
from different species and other DNA sequences including probes and vectors, cell lines from
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were described by their sequence.66 Thus, citing Lilly, the defendants
contended that the patent was invalid for lack of an adequate written
description for the claimed DNA sequences.67
The patentee presented three main arguments to support the
contention that the claimed DNA sequences were adequately
described, all of which were initially rejected by the CAFC.68  The
first argument was that the preferential hybridization ascribed to the
claimed DNA sequences was a binding affinity (referring to the
strength of the chemical interaction between two molecules), and as
such, satisfied the PTO Written Description Guidelines 69 which
provide that the written description requirement for some
biomolecules may be met by providing "examples of identifying
characteristics including a sequence, structure, binding affinity,
binding specificity, molecular weight and length. '' 70  Second, Enzo
contended that describing DNA by hybridization to a target DNA
sequence is an adequate written description since DNA hybridization
is a specific chemical interaction occurring between complementary
sequences.71  The court was unconvinced with both of these
arguments and stated that hybridization of one DNA molecule to
another describes what the DNA does, not what it is, and is therefore
stating the function of the DNA and is an inadequate written
description after Lilly.
72
The final argument in support of the '659 patent was that
possession was shown by an actual reduction to practice and by
deposit of three bacterial strains containing cloned DNA sequences of
the invention at ATCC thereby satisfying a primary purpose of the
written description requirement.73 The court agreed that possession of
the invention had been shown, but disagreed that mere demonstration
of possession was sufficient to satisfy the written description
numerous organisms, including hundreds of human tumor cell lines and embryonic stem cell
lines, microorganisms, plants and other biological materials. These materials are provided upon
request to individuals in universities and private industry as well as governments around the
world. ATCC personnel also perform research, provide technical services and educational
programs with the goal of advancing scientific knowledge.
See http://www.atcc.org/About/AboutATCC.cfm (last visited Nov. 3, 2003).
66. '659 patent, supra note 11.
67. Enzo 1, 285 F.3d at 1018.
68. Id. at 1017-19.
69. Id. at 1017.
70. Written Description Guidelines, 66 Fed. Reg. at 1110 n.42.
71. Enzo l, 285 F.3d at 1018.
72. Id. at 1018-19.
73. Id. at 1022-23.
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requirement because there was insufficient distinguishing information
about the sequences to support the claims.74
Following this decision, Enzo successfully petitioned for a
rehearing, which took place in front of the same three-judge panel.75
In a reversal written by Judge Lourie (who also authored Enzo 1), the
CAFC held this time that a functional description of DNA, if coupled
with a known or disclosed correlation between structure and function,
could satisfy the written description requirement.76 Moreover, a
deposit of biological materials in a public repository could satisfy the
written description requirement, but not because it shows possession
of the invention.77
What rationale supports the court's reversal? First, the court
reexamined the Lilly decision in view of the PTO Written Description
Guidelines and concluded that while a functional description of DNA
in the Lilly case was not an adequate written description, it is
incorrect to conclude that all functional descriptions of DNA are
inadequate written descriptions (emphasis added).78 This is true
because, according to the PTO Written Description Guidelines, the
written description requirement can be met by disclosing sufficiently
detailed identifying characteristics including chemical properties or
functional characteristics when coupled with a known or disclosed
correlation between structure and function. 79  The court was
particularly persuaded in adopting the structure-function correlation
as a means of satisfying the written description requirement by the
fact that the PTO would find a functional claim to an "isolated
antibody capable of binding to antigen X" to be an adequate written
description.80 In the antibody case, the claim describes what the
antibody does but not what it is since it does not list the amino acid
sequence. The written description is sufficient for the antibody, even
though there is no amino acid sequence given for the antibody,
because the structural characteristics of the five classes of antibodies
are well defined, as are the functional characteristics of antibody
binding, and antibody technology is well developed and mature.81
Thus, the court expressly adopted the PTO Written Description
74. Id. at 1021-22.
75. Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316 (Fed. Cir. 2002).
76. Id. at 1324-25.
77. Id. at 1325, 1329-30.
78. Id. at 1324.
79. Id. (citing Written Description Guidelines, 66 Fed. Reg. at 1106).
80. Id.
81. Enzo 11, 296 F.3d at 1324.
[Vol. 20
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Guidelines on this point and noted that if the preferential binding of
the DNA sequences of the '659 patent to the N. gonorrhoeae genome
were correlated with a sufficiently known or disclosed structure, then
the functional claim to such DNA sequences would be valid.82 This
issue was remanded to the lower court.83
Next, the court explained its rationale for holding that deposits
could fulfill the written description requirement. 84  The court
acknowledged the inherent difficulties in adequately describing
unique biological materials and determined that if such materials were
deposited in a public repository, then one skilled in the art would be
able to obtain the materials and literally see the scope of the invention
(here, by sequencing the DNA of the claimed invention) thereby
satisfying the written description requirement.85
Finally, the court made an important distinction between the
depositing of materials to satisfy the written description requirement
and the depositing of materials or actual reduction to practice to show
possession to satisfy the written description requirement.8 6 The court
reiterated its prior holding that showing possession alone does not
satisfy the written description requirement. 87 The written description
requirement "is the quid pro quo of the patent system; the public must
receive meaningful disclosure in exchange for being excluded from
practicing the invention for a limited period of time. 88
In summary, although the court in Enzo H resolved the issues of
whether some functional descriptions of DNA as well as deposits of
biological materials in a public repository could satisfy the written
description requirement, other issues were left for determination by
the district court on remand creating further uncertainty for the
foreseeable future. The most important of these issues is whether the
hybridization function of DNA is correlated with a known structure of
DNA in a manner sufficient to satisfy the written description
requirement. 89 Since the CAFC adopted the PTO Written Description
Guidelines on this point, the district court's determination of this
factual inquiry will likely be determinative.
82. Id. at 1324-25.
83. Id. at 1327.
84. Id. at 1325.
85. Id. at 1326.
86. Id. at 1329.
87. Enzo 11, 296 F.3d at 1330.
88. Id.
89. Id. at 1327-28.
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C. The View That the Written Description Requirement Should
Be Broadly Interpreted.
After the Lilly decision, many commentators viewed the CAFC's
holding as creating a new and heightened written description standard
pertaining solely to biotechnological inventions. 90 The assertion was
that a required demonstration of physical possession would chill the
development of new products and processes in the field.9'
The rationale is explained as follows. Patent law has always
provided protection for alternative embodiments or variants of an
invention that are not expressly described in the patent.92 This
rewards inventors with protection for the full scope of their inventions
and protects their rights by preventing competitors from avoiding
patent infringement by simply making minor changes to the claimed
invention.93 Thus, it is contended that a narrow written description
requirement results in an inability to claim alternative embodiments
thereby limiting the scope of patent protection.94  This chills
investment in research because there is less incentive to invest in
research when the scope of patent protection is limited.95 While this
is a rational and meritorious argument, it fails to address the problem
of overreaching inventors. This is the chief argument of the
proponents of a narrow written description as explained below.
D. The View That the Written Description Requirement Should
Be Narrowly Interpreted
The narrow written description proponents contend that limiting
nucleic acid sequence claims to those supported by a specific listing
of the sequence comports with patent policy and fosters investment in
basic research.96 One commentator applauded the Lilly decision
stating that "any alternative approach to patenting genes, cDNAs, or
mRNAs other than disclosing exact nucleotide sequences risks
granting overly broad patent rights to a single inventor."
97
The rationale for this position is that due to the high degree of
sequence similarity between related species, inventors can merely
90. See, e.g. Mueller, supra note 10 at 649; Rai, supra note 10, at 834.
91. Mueller, supra note 10, at 650.




96. See, e.g., Sampson, supra note 10, at 1261.
97. Id. at 1260.
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clone and sequence a gene from one species and then claim the
homologous gene from all related species, which is precisely what
U.C. did in the patent at issue in Lilly.98 Without a requirement for
listing the exact nucleotide sequence of the claimed DNA, inventors
"could receive patent rights to sequences of which they have no
knowledge, in organisms with which they have never worked." 99
Furthermore, inventors could claim rights to naturally occurring
single-nucleotide variants within a single species, also known as
single-nucleotide polymorphisms, and other gene variants known as
alleles and isoforms. 100"0' Ultimately, this would lead to "nucleotide
sequence claims becoming a Pandora's box that the patent law is
unable to control."'
10 2
Some commentators also argue that narrow patent rights to DNA
sequences foster investment in research. 10 3  The idea is that
companies are encouraged to invest time and resources in cloning
homologous genes and genes encoding protein variants which may
prove more clinically useful than original isolates if the patent field is
still open. 10 4  While this may be true, the argument does not
effectively deal with the contention of the broad written description
proponents that narrow claims encourage companies to design around
existing patents by slightly modifying DNA sequences subject to
patent protection. Such practices could easily undermine the value of
the original patent with detrimental consequences to the
biotechnology industry. This is because biotechnology is particularly
dependent upon strong patent protection due to the lengthy and costly
product development process and the associated high risk of failure.10 5
This is especially true for therapeutic products.'0
6
An additional argument in the written description debate centers
on the impact it will have on the number of patent holders in a given
98. Id. at 1260-61.
99. Id.
100. Id. at 1260.
101. See id. (explaining how these variants are essentially the same gene that code for
essentially the same protein with identical or similar properties and that single nucleotide
variations in genes among individuals give rise to the diversity seen among members of the
same species).
102. Id. at 1261.
103. See, e.g., id.
104. Id.
105. Edward Penhoet, Science & Technology Policy: A CEO's View, 33 CAL. WEST. L.
REV. 15,25-26 (1996).
106. MADHU AGRAWAL, GLOBAL COMPETITIVENESS IN THE PHARMACEUTICAL
INDUSTRY, 123 (1999).
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field. It is the consensus that broad patent claims limit the number of
patent owners and narrow patent claims expand the number of patent
holders. The dispute, then, revolves around whether it is best for the
biotechnology industry to have many different patent holders or few.
The proponents of narrow patent claims contend that it is
undesirable to have a situation where only a few patent holders
control a field. 10 7 This is because of the potential for one or a few
patentees to extract exorbitant licensing fees, secure rights to the
fruits of future research or even close off entire fields of research to
competitors.I°8
But the alternative situation that would occur with narrow patent
claims seems equally unattractive. In this situation, there is a
proliferation and fragmentation of patent rights with the net result that
multiple entities end up owning small pieces of the intellectual
property that cover a final product.'0 9 Such a situation is particularly
problematic when rights are granted to multiple entities covering
early stage basic research,"10 the category of research into which DNA
sequence claims fit."' The problem, deemed the "tragedy of the anti-
commons," 12 is that multiple owners of the property each have a right
to exclude others while no one has an effective privilege of use." 
3
Then, companies seeking to develop products must secure multiple
licenses from multiple entities, each carrying an associated
transaction cost."14  Ultimately, each license represents an obstacle
that the developer of a product must overcome, along with a
transaction cost that will be passed on to the consumer, and the net
107. See Penhoet, supra note 105, at 24-25.
108. AGRAWAL,supra note 106, at 33.
109. Rai, supra note 10, at 839-40.
110. Michael A. Heller & Rebecca S. Eisenberg, Can Patents Deter Innovation? The
Anticommons in Biomedical Research, 280 SCIENCE 698 (1998).
111. In general, DNA sequences are not stand-alone commercial products, with the
exception of the small and highly specialized research products market. To date, DNA
sequences have been used commercially in processes to produce therapeutic proteins and in
diagnostic tests. In both these situations, the claimed DNA is but one part of the product, and in
the case of therapeutic proteins, is not part of the product at all, but rather a part of the
manufacturing process. Even in the field of gene therapy, which envisions using DNA as a
therapeutic agent, the DNA must be combined with a delivery vehicle to make the final product.
Since the discovery and cloning of DNA occurs at the beginning of the research and
development process, and since the DNA is rarely a stand-alone commercial product, DNA
sequences are more properly characterized as the fruits of early stage research as opposed to late
stage product development.
112. Heller & Eisenberg, supra note 110, at 698.
113. Id.
114. Rai, supra note 10, at 839-40.
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effect is a slowing of new products entering the market place at an
increased cost." 5
In considering the arguments made above, it is apparent that
each side has merit. The question then is how to reconcile the
opposing viewpoints in a manner that preserves the traditional
objectives of patent law-to encourage the creation and sharing of
new inventions for the public good. One way is to adopt a new test,
the primary cloning test, explained further below.
III. PROPOSAL: A PRIMARY CLONING TEST FOR APPLICATION OF THE
WRITTEN DESCRIPTION REQUIREMENT TO NUCLEIC ACID
SEQUENCE CLAIMS
One of the considerations absent from the debate over the written
description requirement for nucleic acid sequence claims is the dual
nature of DNA and other nucleic acids. First, they are molecules
subject to discovery and isolation from natural (or primary) biological
sources, and then following isolation or cloning, they become
experimental molecules subject to endless manipulation in the
laboratory. It is in the context of nucleic acid sequence claims to
molecules that have never before been isolated and cloned from a
primary source that a narrow interpretation of the written description
requirement including demonstration of possession of the claimed
invention is most justified.
As an example, in the Lilly case, U.C. did not actually isolate and
clone the human insulin cDNA until two years after filing the
application listing the rat cDNA sequence." 6 Clearly, the U.C.
inventors were not in physical possession of the claimed invention to
human sequences at the time of filing the patent application on the rat
sequence, and a substantial amount of time and effort were still
required to isolate, clone and sequence the human insulin cDNA." 7
Thus, the Lilly decision effectively prevented the U.C. inventors from
overreaching and receiving patent protection for an invention which
they did not possess at the time they filed their application.
However, once DNA is isolated and cloned from a natural
biological source, it becomes an experimental molecule subject to
human manipulation in the laboratory. For example, any cloned DNA
115. Heller & Eisenberg, supra note 110, at 699.
116. Regents of the Univ. of Cal. v. Eli Lilly & Co., 119 F.3d 1559, 1562-63 (Fed. Cir.
1997).
117. See generally HALL, supra note 13 (describing the high-stakes race between three
different research groups to clone the human insulin cDNA at issue in the Lilly case).
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can be fragmented into smaller pieces and recombined with other
DNA to create novel combinations. Moreover, any nucleotide
sequence can be changed base-by-base at will to whatever the
investigator desires it to be." 18 It is in this context of nucleic acid
sequences as experimental molecules that a broad interpretation of the
written description requirement of the claimed invention is most
justified as explained further below.
That is, if an inventor is limited to rights for a specifically listed
DNA sequence, or to DNA sequences demonstrated to be in the
inventor's possession, then it is a simple matter for a would-be
infringer to create a variant of that DNA sequence that will encode the
same protein (due to the degeneracy of the genetic code), or that will
have substantially similar properties. Hundreds, even thousands of
such variants could be created. Patent infringers could operate with
impunity. Since it would be highly inefficient and impractical for an
inventor to list all of the possible variant sequences covered by an
invention merely to prevent infringement, this degree of specificity
has never been required. Thus, broad claims that describe the DNA
by characteristics other than sequence, such as by a structure-function
relationship, will prevent patent infringers from avoiding liability by
making minor changes to the claimed invention. Of course, other
patent doctrines, such as novelty, 1 9 nonobviousness 120 and the
doctrine of equivalents,' 2 1 may also come into play to prevent
infringers from escaping liability.
The proposed primary cloning test addresses the dual nature of
nucleic acids as both the subject of discovery and the subject of
experimental manipulation and is as follows. First, primary cloning
means the isolation and cloning of nucleic acids from a natural or
primary biological source. Thus, for example, the cloning of human
insulin cDNA from the mRNA of human pancreatic islet cells, the
cells in the human body that produce insulin, is primary cloning, but
the subsequent manipulation of that cloned cDNA is not. When
analyzing the adequacy of the written description for a claimed
118. See, e.g., ALBERTS, supra note 27, at 258-71.
119. 35 U.S.C. § 102 (2000).
120. 35 U.S.C. § 103 (2000).
121. The doctrine of equivalents refers to the judicially created doctrine by which courts
extend the literal language of a claim to encompass additional subject matter that is so similar to
that claimed that it is deemed equivalent. More specifically, this means that the infringing
product or process "performs substantially the same function in substantially the same way to
obtain the same result as the claimed subject matter." DONALD S. CHIsuM, 5 CHISUM ON
PATENTS § 18.04 (2002).
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nucleic acid sequence, a court should consider whether the claimed
sequence requires primary cloning, or whether it is a previously
cloned molecule subject to experimental manipulation. When claims
are to nucleic acids requiring primary cloning, then, in addition to
providing a written description as outlined in the PTO Written
Description Guidelines, 22 the heightened requirement of physical
possession of the claimed sequence must also be demonstrated.
Requiring both an adequate written description and a demonstration
of possession comports with a concept articulated by the Enzo H
court: possession and written description are not synonymous. 123
Satisfying both criteria for nucleic acids requiring primary cloning
will provide "meaningful disclosure"' 124 of the invention and prevent
overreaching by inventors who have not expended the effort, skill and
creativity required to clone an original isolate from a biological
source.
Adoption of the primary cloning test would also result in a
requirement for actual reduction to practice. Although not required
for the patentability of inventions in general, a requirement for actual
reduction to practice in this narrow instance is reasonable in view of
the fact that prior to the act of the primary cloning of a nucleic acid,
the only form in which it exists is in nature. It is well established that
natural phenomena are not patentable.' 25
However, if the claimed nucleic acid sequence is an
experimental molecule, other methods of describing the nucleic
acid 126  may be employed such that sufficient identifying
characteristics 27 are disclosed to distinguish the claimed sequence
from others not claimed. Physical possession of all claimed
sequences would not be required. This will allow inventors to protect
the full scope of their inventions and prevent competitors from
avoiding infringement by making minor changes to the claimed
invention.
The primary cloning test thus incorporates the positive aspects of
each side of the written description debate while effectively
addressing the criticisms of each side. By focusing on whether the
claimed nucleic acid requires primary cloning or not, courts can
122. Written Description Guidelines, 66 Fed. Reg. at 1110 n.42.
123. Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316, 1330 (Fed. Cir. 2002).
124. Id.
125. Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980).
126. Written Description Guidelines, 66 Fed. Reg. at 1110 n.42.
127. Id. (explaining that such characteristics include structure, binding affinity, binding
specificity, molecular weight, length or combinations of characteristics).
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adjust the written description and possession requirements
accordingly. By requiring an adequate written description and a
showing of possession for nucleic acids requiring primary cloning,
courts will effectively narrow the scope of the claims. This will
prevent overreaching by inventors, provide incentive and foster
investment in research, and prevent a field from becoming
monopolized by one or a few patent holders. However, by relaxing
the written description requirement for experimental nucleic acids,
courts will effectively broaden the scope of the claims. Then, the full
scope of inventions is protected, investment in research is fostered
and fields of investigation do not become overcrowded with narrow
patents to overlapping inventions.
IV. APPLYING THE PRIMARY CLONING TEST TO THE ENZO '659
PATENT
The broadest claim of the Enzo '659 patent is to nucleotide
sequences that bind preferentially to the genome of N. gonorrhoeae
over the genome of N. meningitides, the preferential binding
determined by following a series of steps beginning with
radioactively labeling the said nucleotide sequence for use as a
probe.128 Thus, the claim is to a nucleic acid probe. This is not a
DNA molecule requiring primary cloning, but rather an experimental
molecule. This is because to be used as a probe in this context, the
DNA must have been previously cloned from a biological source.'
29
Having determined that the claimed sequences are experimental
molecules, the primary cloning test requires a broad construction of
the written description requirement. The holding of the Enzo II court
effectively takes this approach noting that DNA can be described by
function if that function is correlated with a known or described
structure.130 However, the CAFC left the factual determination of
whether the functional DNA claim (here, hybridization) was
sufficiently correlated with a known structure to the lower court.' 3'
How should the lower court approach this structure-function
issue for the claimed nucleotide sequences? The CAFC noted that
functional antibody claims are supported by an adequate written
description because the structural characteristics and binding
128. '659 patent, supra note 11, claim 1.
129. See, e.g., ALBERTS, supra note 27, at 188-89.
130. Enzo Biochem, Inc. v. Gen-Probe, Inc., 296 F.3d 1316, 1324-26 (Fed. Cir. 2002).
131. Id. at 1327.
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functions of antibodies are so well known. 132 The same can be said of
the structural characteristics of nucleic acids and hybridization,
characteristics that have been known to the scientific community and
exploited experimentally for over 40 years.'33 Thus, it would not be
surprising if the lower court determined that the functional claim of
hybridization was correlated with a sufficiently known structure
thereby rendering the written description of Enzo's hybridization
claim adequate.
While such a finding in the case of the Enzo patent may be
justified so that patent protection is awarded to cover the large
number of variants that could be created experimentally simply to
avoid patent infringement, what about other hybridization claims?
What if, in the Lilly case, U.C. had claimed all vertebrate, mammalian
and human cDNA sequences that hybridize to the rat insulin cDNA?
Would insertion of just that one word, "hybridize," into the claim
render a specification with an inadequate written description suddenly
adequate? Clearly, the answer must be "no," otherwise this would
represent a triumph of form over substance. It is for this reason that
the primary cloning test proposed here requires a stricter showing of
physical possession for claims to nucleic acids requiring primary
cloning, such as those at issue in Lilly. Without a showing of physical
possession, inventors "could receive patent rights to sequences of
which they have no knowledge, in organisms with which they have
never worked,"' 134 and perhaps never intend to work.
V. CONCLUSION
Throughout history, the written description requirement for
patented inventions has been one of the most fundamental aspects of
patents and reflects the quidpro quo nature of the patent system. In
exchange for adequately describing the invention to one skilled in the
art, the inventor receives a monopoly for a limited time during which
others can be excluded from making, using or selling the invention.
Recent decisions of the CAFC indicate that the written
description requirement plays an important role in determining the
validity of claims to nucleic acid sequences, yet the court has not
issued clear and consistent standards. In fact, the court itself appears
confused over the proper standards by which to judge the adequacy of
132. Id. at 1324.
133. See, e.g., ALBERTS, supra note 27, at 188-96.
134. Sampson, supra note 10, at 1260-61.
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a written description as reflected by the recent decision in Enzo I
followed by a reversal upon rehearing in Enzo II.
Thus, standards and guidelines are clearly needed to judge the
adequacy of the written description supporting nucleic acid claims.
One view is that the written description requirement should be
broadly interpreted enabling inventors to maximize protection for
their specific invention as well as related alternative embodiments.
The opposing view is that the written description requirement should
be narrowly interpreted thus preventing overreaching by inventors.
Both sides claim that adopting their viewpoint will foster investment
in research and result in the optimal number of patent holders in the
industry.
In truth, both sides have merit and the opposing views can be
reconciled by adopting the primary cloning test advocated here. The
primary cloning test calls for distinguishing nucleic acid sequence
claims between those molecules that have been isolated and cloned
from a natural biological source and those that have not. Claims to
molecules requiring primary cloning deserve heightened scrutiny as
provided by the possession test first adopted by the Fiers court. In
contrast, claims to previously cloned molecules, so-called
experimental molecules, are supported by a broader application of the
written description requirement and do not require a showing of
physical possession. Thus, adoption of the primary cloning test will
incorporate the best of both viewpoints resulting in broad protection
for claims to nucleic acids that can easily be modified experimentally
to avoid infringement and narrow protection for claims to novel
nucleic acids that have not been previously isolated and cloned from a
biological source.
